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Madura foot is a chronic infectious disease, caused by bacterial actinomycetes or by fungi. Mycetoma is endemic in tropical and sub-
tropical areas, where it is a real public health issue. It is a rare and neglected disease in our country. The diagnosis is made by clinical
picture, direct microscopic examination and histological study.
The best therapeutic choice is surgical removal of the lesion, followed by medical treatment. An earlier diagnosis and treatment can
elicit good results. We report a case of eumycetoma in a 33 year-old Moroccan man, rural worker, treated by Ketoconazole in 12 months,
associated with surgical debridement. The evolution was marked by the complete remission of the infection.
 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Madura foot is ﬁrst described by John Gill in 1842 in
Madras, India. It is a localized chronic suppurative infec-
tion of subcutaneous tissue, commonly aﬀecting the foot
(Mohammad et al., 2011). Mycetoma is characterized by
a clinical triad of chronic induration, draining sinuses,
and discharge of granules. It is either actinomycotic or
eumycotic in etiology. It is endemic in tropical and sub-
tropical countries with low precipitation (Kallel et al.,
2005) rare and little known in other countries as Morocco,
where they plagued by sporadic (N’diaye et al., 2000). It
remains as a real cause of disability among population liv-
ing in rural area because this infection is often neglected inhttp://dx.doi.org/10.1016/j.jssdds.2013.12.004
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Peer review under responsibility of King Saud University.the initial stage. We present here a new case of madura foot
in Moroccan patient, diagnosed and treated earlier, with a
good clinical response.
2. Case report
A 33-year-old man, a rural worker, without any signiﬁ-
cant medical history and no records of traveling to tropical
areas, comes to the consultation, with a one-year history of
a progressively enlarging, painful lesion on the sole of his
left foot (Figs. 1 and 2). He was treated by doctors with
analgesic and antibiotic without any improvement.
Examination revealed a tumefaction that discharges a
purulent exudate via skin ﬁstulae, the exudate contains
black granules (Fig. 3). The black grains had a soft consis-
tency and diﬀerent shapes and sizes. Black grains suggest a
fungal infection. There was no regional lymphadenopathy
and no other abnormalities were found. He could not recall
any signiﬁcant trauma to his foot and, had never gone
without footwear. The histological analysis on the cutane-
ous biopsy showed inﬂammatory process in hypodermis
and hyphae, which conﬁrmed the diagnosis of Eumycetom-Saud University.
commons.org/licenses/by-nc-nd/3.0/).
Figure 1. Tumefaction of the sole of the left foot.
Figure 2. Tumefaction of the sole of the left foot discharging black grains.
Figure 3. Black eumycetoma grains.
Figure 4. Histochemical staining (Periodic Acid Schiﬀ) shows hyphae.
Figure 5. Hematoxyline eosin staining: at low magniﬁcation shows a
subacute inﬂammatory process in hypodermis.
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malities in the hemogram. Tests for syphilis and HIV infec-
tion were negative. Serologic tests for hepatitis virus types
B and C were negative. Standard X-rays of his foot showed
no lesion of the bone. The patient was treated by Ketocon-
azole 400 mg/day for 12 months, associated with surgical
debridement. The liver function tests were realized before,every 2 months and after 12 months of treatment, were
normal. The evolution was marked by the complete remis-
sion of the infection.3. Discussion
Mycetoma is a chronic granulomatous inﬂammatory
response involving bacteria or fungi that triggers the for-
mation of grains containing aggregates of the causative
organisms that may be discharged onto the skin surface
through multiple sinuses, causing the progressive develop-
ment of granulation and scar tissue that can cause defor-
mity (Maiti et al., 2002).
In tropical countries, mycetoma is a real public health
issue, but this pathology is quite rare in Morocco (Asly
et al., 2010). A few case reports are published (Hommadi
et al., 2008; El Gandaoui et al., 2004). A retrospective
study was conducted in the dermatology department at
Ibn-Sina Hospital in Rabat, 12 cases of mycetoma were
collected over a period of 14 years. All patients were living
in rural areas and had an agricultural activity. The presence
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three cases and yellowish in one case (Marc et al., 2011).
The type of mycetoma is often suggested by the color of
the grains. Red grains are indicative of an actinomycotic
mycetoma. Black grains are consistent with a eumycetoma,
a white and yellow colored grains are indicative of either
actinomycetoma or eumycetoma (Ahmed et al., 2004).
The diﬀerentiation between eumycetoma and actinomy-
cetoma is an important one with regard to therapy (Welsh
et al., 2007). The combination of the clinical speciﬁc
lesions, typical grains and the histopathological appearance
(presence of a granulomatous inﬂammatory reaction with
abscesses containing granules of the infecting organism)
is characteristic of the diagnosis.
X-rays, tomography, and magnetic resonance imaging
are all useful to determine the extension of the lesions in
bone and other tissues (Elmaataoui et al., 2011).
Commencement of treatment at an early stage is neces-
sary to prevent complication, as shown in our case (Lupi
et al., 2005). Combined medical and surgical treatment is
the standard to follow in mycetoma. The medical treatment
consists of antibiotic therapy (cotrimoxazole, amikacin or
minocycline) for actinomycetes or antifungal therapy
(ketoconazole or itraconazole) for eumycetoma
(Mahgoub and Gumaa, 1984). In resistant cases of eumyce-
toma, various antifungals (terbinaﬁne, posaconazole,
voriconazole, caspofungin and anidulafungin) are indi-
cated (Estrada et al., 2012). A prospective study showed
that Itraconazole in a starting dose of 400 mg then
200 mg for the treatment of patients with mycetoma due
to Madurella mycetomatis is safe and well tolerated with
minimal side eﬀects. And it is recommended to give itraco-
nazole in a high dose (400 mg) preoperatively to facilitate
lesion localization by ﬁbrosis (Fahal et al., 2011).
Surgery is indicated in mycetoma for resistance to med-
ical treatment, better response to medical treatment in
patients with massive disease or for localized lesions. The
surgical options range from local excisions to amputations.
Amputation is indicated in advanced mycetoma not
responding to medical treatment with severe secondary
bacterial infection (Smith and Kutbi, 1998), hence the
importance of earlier diagnosis and treatment.
4. Conclusion
Madura foot is a chronic disease relatively rare in our
country. It is probably underestimated. However, it might
be encountered in our practicing life. The dermatologistmust be aware of this entity. Eumycetoma is a fungal dis-
ease that requires an early, accurate diagnosis. Medical
treatment and surgical measures could be of great beneﬁt
for these patients, a delayed diagnosis leading to functional
and esthetical impairments.
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